Globus Medical Slides After Full-Year Revenue Guidance Held Steady

Dow Jones

May 09

By Christopher Kuo

Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue.

The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date.

The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion.

The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said.

Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said.

The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier.

Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share.

Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million.

The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share.

(MORE TO FOLLOW) Dow Jones Newswires

May 08, 2026 15:11 ET (19:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2634461836"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634461836\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634461836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 03:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634461836","market":"other","top_or_hot":-1,"title":"Globus Medical Slides After Full-Year Revenue Guidance Held Steady","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n</p>\n<p>\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n</p>\n<p>\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n</p>\n<p>\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n</p>\n<p>\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n</p>\n<p>\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n</p>\n<p>\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n</p>\n<p>\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:11 ET (19:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Globus Medical Slides After Full-Year Revenue Guidance Held Steady</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobus Medical Slides After Full-Year Revenue Guidance Held Steady\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 03:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n</p>\n<p>\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n</p>\n<p>\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n</p>\n<p>\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n</p>\n<p>\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n</p>\n<p>\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n</p>\n<p>\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n</p>\n<p>\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:11 ET (19:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GMED","symbol_name":"Globus Medical Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634461836","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634461836","pubTimestamp":1778267460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue.The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date.The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion.The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said.Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said.The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier.Adjusted earnings came in at $1.12 a share. Analysts polled by FactSe","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GMED":"Globus Medical Inc"},"translate_title":"Globus Medical在全年收入指引保持稳定后下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMED":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n\n\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n\n\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n\n\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n\n\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n\n\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n\n\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n\n\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n\n\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n\n\n \n\n\n  (MORE TO FOLLOW) Dow Jones Newswires\n\n\n  May 08, 2026 15:11 ET (19:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}